المؤلفون: Brown M.R., Vajdic C.M., Delaney G.P., Hong S., Hunt L., Webber K., Pearson S.-A., Van Leeuwen M.T., Luu S., Gurney H.

مصطلحات الفهرس: meta analysis, multiple myeloma/dt [Drug Therapy], observational study, oncology, ovary cancer/dt [Drug Therapy], peer review, phase 2 clinical trial (topic), phase 3 clinical trial (topic), priority journal, prostate cancer/dt [Drug Therapy], QT prolongation/si [Side Effect], randomized controlled trial (topic), review, systematic review, venous thromboembolism/si [Side Effect], abiraterone/ae [Adverse Drug Reaction], abiraterone/ct [Clinical Trial], abiraterone/dt [Drug Therapy], aflibercept/ae [Adverse Drug Reaction], aflibercept/ct [Clinical Trial], androgen receptor/ec [Endogenous Compound], axitinib/ae [Adverse Drug Reaction], axitinib/ct [Clinical Trial], bevacizumab/ae [Adverse Drug Reaction], bevacizumab/ct [Clinical Trial], bevacizumab/dt [Drug Therapy], cediranib/ae [Adverse Drug Reaction], cediranib/ct [Clinical Trial], cetuximab/ae [Adverse Drug Reaction], cetuximab/ct [Clinical Trial], cytochrome P450 family 17/ec [Endogenous Compound], enzalutamide/ae [Adverse Drug Reaction], enzalutamide/ct [Clinical Trial], enzalutamide/dt [Drug Therapy], epidermal growth factor receptor 2/ec [Endogenous Compound], estrogen receptor alpha/ec [Endogenous Compound], estrogen receptor beta/ec [Endogenous Compound], Flt3 ligand/ec [Endogenous Compound], lenalidomide/ae [Adverse Drug Reaction], lenalidomide/ct [Clinical Trial], lenalidomide/dt [Drug Therapy], nintedanib/ae [Adverse Drug Reaction], nintedanib/ct [Clinical Trial], panitumumab/ae [Adverse Drug Reaction], panitumumab/ct [Clinical Trial], pazopanib/ae [Adverse Drug Reaction], pazopanib/ct [Clinical Trial], platelet derived growth factor alpha receptor/ec [Endogenous Compound], platelet derived growth factor beta receptor/ec [Endogenous Compound], protein Ret/ec [Endogenous Compound], Raf protein/ec [Endogenous Compound], ramucirumab/ae [Adverse Drug Reaction], ramucirumab/ct [Clinical Trial], sorafenib/ae [Adverse Drug Reaction], sorafenib/ct [Clinical Trial], sorafenib/dt [Drug Therapy], sunitinib/ae [Adverse Drug Reaction], sunitinib/ct [Clinical Trial], tamoxifen/ae [Adverse Drug Reaction], tamoxifen/ct [Clinical Trial], tamoxifen/dt [Drug Therapy], thalidomide/ae [Adverse Drug Reaction], thalidomide/ct [Clinical Trial], thalidomide/dt [Drug Therapy], transcription factor/ec [Endogenous Compound], trastuzumab/ae [Adverse Drug Reaction], trastuzumab/ct [Clinical Trial], trastuzumab/dt [Drug Therapy], unclassified drug, vandetanib/ae [Adverse Drug Reaction], vandetanib/ct [Clinical Trial], vandetanib/dt [Drug Therapy], vasculotropin A/ec [Endogenous Compound], vasculotropin receptor 1/ec [Endogenous Compound], vasculotropin receptor 3/ec [Endogenous Compound], cytochrome P450 family 17a1/ec [Endogenous Compound], lymphoid transcription factor ikzf1/ec [Endogenous Compound], lymphoid transcription factor ikzf3/ec [Endogenous Compound], molecularly targeted therapy, arterial thromboembolism/si [Side Effect], breast cancer/dt [Drug Therapy], cardiology, cardiotoxicity/si [Side Effect], castration resistant prostate cancer/dt [Drug Therapy], clinician, Cochrane Library, cohort analysis, congestive heart failure/si [Side Effect], controlled study, drug megadose, Embase, female, general practice, heart left ventricle ejection fraction, human, hypertension/si [Side Effect], low drug dose, lung cancer/dt [Drug Therapy], male, Medline, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/27204
JNCI Cancer Spectrum
LibKey Link

المؤلفون: Burger H.G.

مصطلحات الفهرس: cardiovascular disease/et [Etiology], clinical trial, triacylglycerol, controlled study, controlled clinical trial, conference paper, adult, aged, bone density, bone mineral, breast cancer/dt [Drug Therapy], drug effect, endometrium cancer/et [Etiology], endometrium hyperplasia/et [Etiology], female, human, major clinical study, postmenopause osteoporosis/dt [Drug Therapy], priority journal, randomized controlled trial, thromboembolism/et [Etiology], high density lipoprotein cholesterol, low density lipoprotein cholesterol, placebo, raloxifene/ct [Clinical Trial], raloxifene/dt [Drug Therapy], selective estrogen receptor modulator/ct [Clinical Trial], selective estrogen receptor modulator/dt [Drug Therapy], tamoxifen/ct [Clinical Trial], tamoxifen/dt [Drug Therapy], Conference Paper

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/26898
Hormone Research
Click here for full text options
LibKey Link

المؤلفون: Oehler M.K., Fung A., Jobling T.W.

مصطلحات الفهرس: drug tolerability, endometrium cancer/dt [Drug Therapy], endometrium cancer/rt [Radiotherapy], endometrium cancer/su [Surgery], endometrium cancer/th [Therapy], histopathology, human, hyperthermic therapy, fulvestrant/ct [Clinical Trial], laparoscopic surgery, laparotomy, meta analysis, nonhuman, postmenopause, review, salpingooophorectomy, sentinel lymph node biopsy, anastrozole/ct [Clinical Trial], anastrozole/dt [Drug Therapy], anastrozole/po [Oral Drug Administration], angiogenesis inhibitor/dt [Drug Therapy], angiogenesis inhibitor/pd [Pharmacology], antineoplastic agent/ae [Adverse Drug Reaction], antineoplastic agent/ct [Clinical Trial], antineoplastic agent/cb [Drug Combination], antineoplastic agent/cm [Drug Comparison], antineoplastic agent/dt [Drug Therapy], antineoplastic agent/pr [Pharmaceutics], antineoplastic agent/pd [Pharmacology], aromatase inhibitor/ct [Clinical Trial], aromatase inhibitor/dt [Drug Therapy], aromatase inhibitor/po [Oral Drug Administration], cisplatin/ct [Clinical Trial], cisplatin/cb [Drug Combination], cisplatin/cm [Drug Comparison], cisplatin/dt [Drug Therapy], doxorubicin/ae [Adverse Drug Reaction], doxorubicin/ct [Clinical Trial], doxorubicin/cb [Drug Combination], doxorubicin/cm [Drug Comparison], doxorubicin/dt [Drug Therapy], doxorubicin/pr [Pharmaceutics], epirubicin/ct [Clinical Trial], epirubicin/cb [Drug Combination], epirubicin/dt [Drug Therapy], everolimus/ct [Clinical Trial], everolimus/dt [Drug Therapy], everolimus/po [Oral Drug Administration], fluorouracil/ct [Clinical Trial], fluorouracil/cb [Drug Combination], fluorouracil/dt [Drug Therapy], gestagen/ct [Clinical Trial], gestagen/cb [Drug Combination], gestagen/dt [Drug Therapy], gestagen/po [Oral Drug Administration], gestagen/pa [Parenteral Drug Administration], gestagen/pr [Pharmaceutics], gonadorelin derivative/dt [Drug Therapy], letrozole/dt [Drug Therapy], liposome/pr [Pharmaceutics], mammalian target of rapamycin/ec [Endogenous Compound], medroxyprogesterone acetate/ct [Clinical Trial], medroxyprogesterone acetate/cb [Drug Combination], medroxyprogesterone acetate/dt [Drug Therapy], megestrol acetate/ct [Clinical Trial], megestrol acetate/dt [Drug Therapy], paclitaxel/ct [Clinical Trial], paclitaxel/cb [Drug Combination], paclitaxel/dt [Drug Therapy], rapamycin/pd [Pharmacology], tamoxifen/ct [Clinical Trial], tamoxifen/cb [Drug Combination], tamoxifen/dt [Drug Therapy], temsirolimus/ct [Clinical Trial], temsirolimus/dt [Drug Therapy], temsirolimus/pd [Pharmacology], trastuzumab/ct [Clinical Trial], trastuzumab/dt [Drug Therapy], trastuzumab/pd [Pharmacology], unclassified drug, vasculotropin, caelix, vasculotropin trap/ct [Clinical Trial], vasculotropin trap/dt [Drug Therapy], vasculotropin trap/pd [Pharmacology], hysterectomy, fulvestrant/dt [Drug Therapy], antineoplastic activity, bone marrow toxicity/si [Side Effect], cancer chemotherapy, cancer hormone therapy, cancer mortality, cancer radiotherapy, cancer staging, cancer survival, cardiotoxicity/si [Side Effect], clinical trial, conservative treatment, drug delivery system, drug efficacy, drug formulation, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/32265
Click here for full text options
LibKey Link

المؤلفون: Oehler M.K., Fung A., Jobling T.W.

مصطلحات الفهرس: drug tolerability, endometrium cancer/dt [Drug Therapy], endometrium cancer/rt [Radiotherapy], endometrium cancer/su [Surgery], endometrium cancer/th [Therapy], histopathology, human, hyperthermic therapy, fulvestrant/ct [Clinical Trial], laparoscopic surgery, laparotomy, meta analysis, nonhuman, postmenopause, review, salpingooophorectomy, sentinel lymph node biopsy, anastrozole/ct [Clinical Trial], anastrozole/dt [Drug Therapy], anastrozole/po [Oral Drug Administration], angiogenesis inhibitor/dt [Drug Therapy], angiogenesis inhibitor/pd [Pharmacology], antineoplastic agent/ae [Adverse Drug Reaction], antineoplastic agent/ct [Clinical Trial], antineoplastic agent/cb [Drug Combination], antineoplastic agent/cm [Drug Comparison], antineoplastic agent/dt [Drug Therapy], antineoplastic agent/pr [Pharmaceutics], antineoplastic agent/pd [Pharmacology], aromatase inhibitor/ct [Clinical Trial], aromatase inhibitor/dt [Drug Therapy], aromatase inhibitor/po [Oral Drug Administration], cisplatin/ct [Clinical Trial], cisplatin/cb [Drug Combination], cisplatin/cm [Drug Comparison], cisplatin/dt [Drug Therapy], doxorubicin/ae [Adverse Drug Reaction], doxorubicin/ct [Clinical Trial], doxorubicin/cb [Drug Combination], doxorubicin/cm [Drug Comparison], doxorubicin/dt [Drug Therapy], doxorubicin/pr [Pharmaceutics], epirubicin/ct [Clinical Trial], epirubicin/cb [Drug Combination], epirubicin/dt [Drug Therapy], everolimus/ct [Clinical Trial], everolimus/dt [Drug Therapy], everolimus/po [Oral Drug Administration], fluorouracil/ct [Clinical Trial], fluorouracil/cb [Drug Combination], fluorouracil/dt [Drug Therapy], gestagen/ct [Clinical Trial], gestagen/cb [Drug Combination], gestagen/dt [Drug Therapy], gestagen/po [Oral Drug Administration], gestagen/pa [Parenteral Drug Administration], gestagen/pr [Pharmaceutics], gonadorelin derivative/dt [Drug Therapy], letrozole/dt [Drug Therapy], liposome/pr [Pharmaceutics], mammalian target of rapamycin/ec [Endogenous Compound], medroxyprogesterone acetate/ct [Clinical Trial], medroxyprogesterone acetate/cb [Drug Combination], medroxyprogesterone acetate/dt [Drug Therapy], megestrol acetate/ct [Clinical Trial], megestrol acetate/dt [Drug Therapy], paclitaxel/ct [Clinical Trial], paclitaxel/cb [Drug Combination], paclitaxel/dt [Drug Therapy], rapamycin/pd [Pharmacology], tamoxifen/ct [Clinical Trial], tamoxifen/cb [Drug Combination], tamoxifen/dt [Drug Therapy], temsirolimus/ct [Clinical Trial], temsirolimus/dt [Drug Therapy], temsirolimus/pd [Pharmacology], trastuzumab/ct [Clinical Trial], trastuzumab/dt [Drug Therapy], trastuzumab/pd [Pharmacology], unclassified drug, vasculotropin, caelix, vasculotropin trap/ct [Clinical Trial], vasculotropin trap/dt [Drug Therapy], vasculotropin trap/pd [Pharmacology], hysterectomy, fulvestrant/dt [Drug Therapy], antineoplastic activity, bone marrow toxicity/si [Side Effect], cancer chemotherapy, cancer hormone therapy, cancer mortality, cancer radiotherapy, cancer staging, cancer survival, cardiotoxicity/si [Side Effect], clinical trial, conservative treatment, drug delivery system, drug efficacy, drug formulation, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/32265
LibKey Link

المؤلفون: Burger H.G.

مصطلحات الفهرس: cardiovascular disease/et [Etiology], clinical trial, triacylglycerol, controlled study, controlled clinical trial, conference paper, adult, aged, bone density, bone mineral, breast cancer/dt [Drug Therapy], drug effect, endometrium cancer/et [Etiology], endometrium hyperplasia/et [Etiology], female, human, major clinical study, postmenopause osteoporosis/dt [Drug Therapy], priority journal, randomized controlled trial, thromboembolism/et [Etiology], high density lipoprotein cholesterol, low density lipoprotein cholesterol, placebo, raloxifene/ct [Clinical Trial], raloxifene/dt [Drug Therapy], selective estrogen receptor modulator/ct [Clinical Trial], selective estrogen receptor modulator/dt [Drug Therapy], tamoxifen/ct [Clinical Trial], tamoxifen/dt [Drug Therapy], Conference Paper

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/26898
Hormone Research
LibKey Link

المؤلفون: Jones A., Omara-Boto T.A., Onwude J., Phillips K., Price J., Samtaney N., Seif M., Doe A., Foster E., Woolas R., Buyse M., Wale C., Margolese R., Body J.J., Duffy S., Jackson T.L., Lansdown M., Philips K., Wells M., Pollard S., Clack G., Coibion M., Bianco A.R., Adams J., Baum M., Buzdar A., Cella D., Coleman R., Constenla M., Cuzick J., Distler W., Dowset M., Eastell R., Fallowfield L.J., Forbes J., George W.D., Gray J., Guastalla J.-P., Hellmund R., Hoctin-Boes G., Houghton J., Williams N., Howell A., Klijn J.G.M., Locker G.Y., Mackey J., Mansel R.E., Nabholtz J.M., Naglkalnai T., Nicolucci A., Nylen U., Sainsbury R., Sapunar F., Suarez-Mendez V.J., Tobias J.S., Friedlander M., Richardson G., Makar A., Neven P., Mention J., Distler D.W., Eiermann W., Mouritis M., Wamsteker, Campos O., Candeias O.R., Landers G., Llombart A., Menjon S., Repolles M., Lindahl B., Ingvar C., Bharbra K., Bjornsson S., Charnock F., Cutner A., De Bono M., Evans-Jones J., Glass M., Holt S., Kremer, O'Donovan P.

مصطلحات الفهرس: tamoxifen/ct [Clinical Trial], adult, article, breast cancer/dt [Drug Therapy], cancer combination chemotherapy, cancer patient, cancer risk, clinical protocol, clinical trial, controlled clinical trial, controlled study, data analysis, double blind procedure, drug efficacy, drug tolerability, endometrial disease/di [Diagnosis], endometrial disease/si [Side Effect], endometrial disease/su [Surgery], endometrium cancer/si [Side Effect], endometrium polyp/di [Diagnosis], endometrium polyp/si [Side Effect], endometrium polyp/su [Surgery], female, human, incidence, major clinical study, multicenter study, randomized controlled trial, statistical significance, treatment duration, anastrozole/ae [Adverse Drug Reaction], anastrozole/ct [Clinical Trial], anastrozole/cb [Drug Combination], anastrozole/cm [Drug Comparison], anastrozole/dt [Drug Therapy], aromatase inhibitor/ae [Adverse Drug Reaction], aromatase inhibitor/ct [Clinical Trial], aromatase inhibitor/cb [Drug Combination], aromatase inhibitor/cm [Drug Comparison], aromatase inhibitor/dt [Drug Therapy], placebo, tamoxifen/ae [Adverse Drug Reaction], tamoxifen/cb [Drug Combination], tamoxifen/cm [Drug Comparison], tamoxifen/dt [Drug Therapy], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/31988
Human Reproduction
Click here for full text options
LibKey Link

المؤلفون: Jones A., Omara-Boto T.A., Onwude J., Phillips K., Price J., Samtaney N., Seif M., Doe A., Foster E., Woolas R., Buyse M., Wale C., Margolese R., Body J.J., Duffy S., Jackson T.L., Lansdown M., Philips K., Wells M., Pollard S., Clack G., Coibion M., Bianco A.R., Adams J., Baum M., Buzdar A., Cella D., Coleman R., Constenla M., Cuzick J., Distler W., Dowset M., Eastell R., Fallowfield L.J., Forbes J., George W.D., Gray J., Guastalla J.-P., Hellmund R., Hoctin-Boes G., Houghton J., Williams N., Howell A., Klijn J.G.M., Locker G.Y., Mackey J., Mansel R.E., Nabholtz J.M., Naglkalnai T., Nicolucci A., Nylen U., Sainsbury R., Sapunar F., Suarez-Mendez V.J., Tobias J.S., Friedlander M., Richardson G., Makar A., Neven P., Mention J., Distler D.W., Eiermann W., Mouritis M., Wamsteker, Campos O., Candeias O.R., Landers G., Llombart A., Menjon S., Repolles M., Lindahl B., Ingvar C., Bharbra K., Bjornsson S., Charnock F., Cutner A., De Bono M., Evans-Jones J., Glass M., Holt S., Kremer, O'Donovan P.

مصطلحات الفهرس: tamoxifen/ct [Clinical Trial], adult, article, breast cancer/dt [Drug Therapy], cancer combination chemotherapy, cancer patient, cancer risk, clinical protocol, clinical trial, controlled clinical trial, controlled study, data analysis, double blind procedure, drug efficacy, drug tolerability, endometrial disease/di [Diagnosis], endometrial disease/si [Side Effect], endometrial disease/su [Surgery], endometrium cancer/si [Side Effect], endometrium polyp/di [Diagnosis], endometrium polyp/si [Side Effect], endometrium polyp/su [Surgery], female, human, incidence, major clinical study, multicenter study, randomized controlled trial, statistical significance, treatment duration, anastrozole/ae [Adverse Drug Reaction], anastrozole/ct [Clinical Trial], anastrozole/cb [Drug Combination], anastrozole/cm [Drug Comparison], anastrozole/dt [Drug Therapy], aromatase inhibitor/ae [Adverse Drug Reaction], aromatase inhibitor/ct [Clinical Trial], aromatase inhibitor/cb [Drug Combination], aromatase inhibitor/cm [Drug Comparison], aromatase inhibitor/dt [Drug Therapy], placebo, tamoxifen/ae [Adverse Drug Reaction], tamoxifen/cb [Drug Combination], tamoxifen/cm [Drug Comparison], tamoxifen/dt [Drug Therapy], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/31988
Human Reproduction
LibKey Link